Table 1.
Variable | N | % | HR (95%CI) | P-value |
---|---|---|---|---|
Total population | 96 | |||
Gleason score | 0.937 | |||
3+4 | 63 | 41.2 | 0.96 (0.32–2.88) | |
4+3 | 33 | 21.6 | 1.00 | |
Pathologic stage | 0.036 | |||
Extraprostatic extension (pT3+) | 22 | 22.9 | 3.26 (1.08–9.80) | |
Prostate-limited (pT2) | 74 | 77.1 | 1.00 | |
Lymph node involvement | 0.116 | |||
Yes (pN1) | 3 | 3.1 | 3.52 (0.74–16.81) | |
No (pN0) | 93 | 96.9 | 1.00 | |
Surgical margin involvement | 0.016 | |||
Yes (pR1) | 40 | 41.7 | 4.86 (1.35–17.54) | |
No (pR0) | 56 | 58.3 | 1.00 | |
Non-Localized Tumor Indicator* | 0.022 | |||
Yes | 50 | 52.1 | 5.75 (1.28–25.74) | |
No | 46 | 47.9 | 1.00 | |
N | Mean (SD) | HR (95%CI) | P-value | |
| ||||
Age (years) | 90 | 61.1 (6.6) | 1.05 (0.97–1.14) | 0.257 |
Pre-operative PSA (ng/mL) | 96 | 7.4 (5.2) | 1.06 (1.00–1.13) | 0.070 |
Non-Localized Tumor Indicator is a summary metric of tumor confined to prostate. ‘Yes’ indicates extraprostatic extension (pathologic stage pT3+), involved lymph nodes (pN1), and/or positive surgical margins (pR1).